NCNoah D. Carrillo

Noah D. Carrillo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Noah D. Carrillo has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Poorwa Awasthi

    University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, School of Medicine and Public Health; 1111 Highland Avenue, Madison, WI 53705, USA

    5 shared publications
  • Vincent L. Cryns

    University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, School of Medicine and Public Health; 1111 Highland Avenue, Madison, WI 53705, USA; Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health; 1111 Highland Avenue, Madison, WI 53705, USA

    5 shared publications
  • Richard A. Anderson

    University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, School of Medicine and Public Health; 1111 Highland Avenue, Madison, WI 53705, USA

    4 shared publications
  • Dhruv Brahmbhatt

    University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, School of Medicine and Public Health; 1111 Highland Avenue, Madison, WI 53705, USA; Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health; 1111 Highland Avenue, Madison, WI 53705, USA

    3 shared publications
  • Mo Chen

    Laboratory of Oral Homeostatic Medicine, School of Medicine and SUSTech Homeostatic Medicine Institute (SHMI), Southern University of Science and Technology, Shenzhen, China

    3 shared publications
  • Tianmu Wen

    University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, School of Medicine and Public Health; 1111 Highland Avenue, Madison, WI 53705, USA

    3 shared publications

Latest Publications

  • Open Access

    Lipid transfer proteins and PI4KIIα initiate nuclear p53-phosphoinositide signaling

    by Noah D. Carrillo, Mo Chen, Poorwa Awasthi, Tianmu Wen, Xue Yang, Colin Sterling, Dhruv Brahmbhatt, Vincent L. Cryns, Richard A. Anderson


  • Open Access

    Lipid transfer proteins and PI4KIIα generate a phosphoinositide-linked proteome

    by Noah D. Carrillo, Mo Chen, Poorwa Awasthi, Tianmu Wen, Xiangqin Chen, Giang Vu, Dhruv Brahmbhatt, Michael Herlihy, Benjamin B. Minkoff, Michael Sussman, et al.


  • Open Access

    Regulation of NRF2 by stably associated phosphoinositides and small heat shock proteins in response to stress

    by Changliang Chen, Noah D. Carrillo, Mo Chen, Tianmu Wen, Poorwa Awasthi, Richard A. Anderson, Vincent L. Cryns


  • Open Access

    Regulation of NRF2 by Phosphoinositides and Small Heat Shock Proteins

    by Changliang Chen, Mo Chen, Tianmu Wen, Poorwa Awasthi, Noah D. Carrillo, Richard A. Anderson, Vincent L. Cryns

    Reactive oxygen species (ROS) are generated by aerobic metabolism, and their deleterious effects are buffered by the cellular antioxidant response, which prevents oxidative stress. The nuclear factor erythroid 2-related factor 2 (NRF2) is a master transcriptional regulator of the antioxidant response. Basal levels of NRF2 are kept low by ubiquitin-dependent degradation of NRF2 by E3 ligases, including the Kelch-like ECH-associated protein 1 (KEAP1). Here, we show that the stability and function of NRF2 is regulated by the type I phosphatidylinositol phosphate kinase γ (PIPKIγ), which binds NRF2 and transfers its product phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P 2 ) to NRF2. PtdIns(4,5)P 2 binding recruits the small heat shock protein HSP27 to the complex. Silencing PIPKIγ or HSP27 destabilizes NRF2, reduces expression of its target gene HO-1, and sensitizes cells to oxidative stress. These data demonstrate an unexpected role of phosphoinositides and HSP27 in regulating NRF2 and point to PIPKIγ and HSP27 as drug targets to destabilize NRF2 in cancer. In brief: Phosphoinositides are coupled to NRF2 by PIPKIγ, and HSP27 is recruited and stabilizes NRF2, promoting stress-resistance.


  • Open Access

    Lipid Transfer Proteins and PI4KIIα Initiate Nuclear p53-Phosphoinositide Signaling

    by Noah D. Carrillo, Mo Chen, Tianmu Wen, Poorwa Awasthi, Colin Sterling, Dhruv Brahmbhatt, Vincent L. Cryns, Richard A. Anderson

    Summary: Phosphoinositide (PIP n ) messengers are present in non-membranous regions of nuclei where they are assembled into a phosphatidylinositol (PI) 3-kinase (PI3K)/Akt pathway that is distinct from the cytosolic membrane-localized pathway. In the nuclear pathway, PI kinases/phosphatases bind the p53 tumor suppressor protein (wild-type and mutant) to generate p53-PIP n complexes (p53-PIP n signalosome) that activate Akt by a PI3,4,5P 3 -dependent mechanism in non-membranous regions of the nucleus. This pathway is dependent on a source of nuclear PIP n s that is poorly characterized. Here we report that a subset of PI transfer proteins (PITPs), which transport PI between membranes to enable membrane-localized PIP n synthesis, also interact with p53 in the nucleus upon genotoxic stress. Class I PITPs (PITPα/β) specifically supply the PI required for the generation of p53-PIP n complexes and subsequent signaling in the nucleus. Additionally, the PI 4-kinase PI4KIIα binds to p53 and the PITPs to catalyze the formation of p53-PI4P. p53-PI4P is then sequentially phosphorylated to synthesize p53-PIP n complexes that regulate p53 stability, nuclear Akt activation and genotoxic stress resistance. In this way, PITPα/β and PI4KIIα bind p53 and collaborate to initiate p53-PIP n signaling by mechanisms that require PI transfer by PITPα/β and the catalytic activity of PI4KIIα. Moreover, the identification of these critical upstream regulators of p53-PIP n signaling point to PITPα/β and PI4KIIα as potential therapeutic targets in this pathway for diseases like cancer. In Breif: Phosphatidylinositol transfer proteins and a PI 4-kinase initiate nuclear p53-PIP n signaling in membrane-free regions.


  • Open Access

    Aryl hydrocarbon receptor knockout accelerates PanIN formation and fibro-inflammation in a mutant Kras -driven pancreatic cancer model

    by Morgan T. Walcheck, Patrick B. Schwartz, Noah D. Carrillo, Kristina A. Matkowsky, Manabu Nukaya, Christopher A. Bradfield, Sean M. Ronnekleiv-Kelly

    Objectives: The pathogenesis of pancreas cancer (PDAC) remains poorly understood, hindering efforts to develop a more effective therapy for PDAC. Recent discoveries show the aryl hydrocarbon receptor (AHR) plays a crucial role in the pathogenesis of several cancers, and can be targeted for therapeutic effect. However, its involvement in PDAC remains unclear. Therefore, we evaluated the role of AHR in the development of PDAC in vivo . Methods: We created a global AHR-null, mutant Kras -driven PDAC mouse model (A -/- KC) and evaluated the changes in PDAC precursor lesion formation (Pan-IN 1, 2, and 3) and associated fibro-inflammation between KC and A -/- KC at 5 months of age. We then examined the changes in the immune microenvironment followed by single-cell RNA-sequencing analysis to evaluate concomitant transcriptomic changes. Results: We found a significant increase in PanIN-1 lesion formation and PanIN-1 associated fibro-inflammatory infiltrate in A -/- KC vs KC mice. This was associated with significant changes in the adaptive immune system, particularly a decrease in the CD4+/CD8+ T-cell ratio, as well as a decrease in the T-regulatory/Th17 T-cell ratio suggesting unregulated inflammation. Conclusion: These findings show the loss of AHR results in heightened Kras -induced PanIN formation, through modulation of immune cells within the pancreatic tumor microenvironment.